Novo Nordisk launches weekly insulin shot Awiqli in India

Danish drugmaker Novo ​Nordisk launched its weekly basal insulin injection, Awiqli, in India ⁠on Thursday (July 9, 2026), aiming to compete with daily-dose options on the market.

Awiqli, which Novo describes as the world’s first once-weekly basal, or background long-acting, insulin approved for clinical use, ‌is prescribed for the treatment of type 1 and type 2 diabetes in adults, the company said.

It is ‌designed to reduce the number of injections from 365 per year ‌to ⁠52, Novo said. A once-weekly dose of 70 insulin units of ⁠Awiqli is priced at ₹261 ($2.74), Novo Nordisk India Managing Director Vikrant Shrotriya told reporters at the launch in New Delhi.